iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption

Press/Media

Period29 Dec 2020

Media coverage

1

Media coverage

  • TitleiCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
    Media name/outletIndia Pharma News
    Country/TerritoryIndia
    Date29/12/20
    PersonsMichael Klein